KEYRUS CRO ACTIVITY sold to ASTEK

The international player in management consulting, data, and artificial intelligence enters into exclusive negotiations with Astek for the sale of its CRO activities.

The acquisition of KEYRUS’ Life Sciences CRO activities would enable Astek to strengthen its value proposition by offering a comprehensive and integrated offering to its Life Sciences clients, combining clinical expertise and technological innovation.

With more than 230 employees in France, Belgium, Canada, and the United States, KEYRUS’ Life Sciences CRO activities support leading clients in the European and North American markets in the design, management, and analysis of clinical trials. These activities also benefit from a presence in North Africa and India.

The offer covers the entire development cycle: clinical and regulatory development (development plans, submissions to health authorities, methodological design), clinical operations (trial management, monitoring, data management, biostatistics), medical writing, and management of non-interventional studies.

With the proposed acquisition, Astek’s Life Sciences division will gather more than 1,200 employees worldwide and will benefit from the Group’s significant offshore capabilities in Poland and India, which bring together 700 experts dedicated to Life Sciences and biostatistics. Astek’s CRO branch, which aims to regroup all of its CRO brands under a common umbrella, will become a major player in mid-size CRO globally, consolidating the Group’s position in a high-value-added and rapidly evolving sector.